Analysis shows improved clinical efficacy and prostate health in patients treated with Qianlie Shutong capsule and tamsulosin, suggesting a beneficial combination therapy.
Chronic prostatitis (CP) is one of the most common health issues in the male urinary system. In this study, we included 110 patients with CP as research subjects and divided them into a research group receiving Qianlie Shutong Capsule (QLSTC) combined with tamsulosin and a control group receiving tamsulosin monotherapy. Comparing their clinical efficacy, we found that the total effective rate of treatment in the research group was higher than that in the control group (P<0.05) and the clinical symptoms of CP were more significantly improved. Meanwhile, comparing the prostate function between the two groups, it was also seen that the small particle of lecithin (SBC) in the prostate fluid of the research group increased significantly after treatment (P<0.05). In addition, comparing the nutritional status of the two groups, we also found that the research group had better nutritional status after treatment. As for safety, there was no significant difference between the two groups (P>0.05). It can be seen that QLSTC combined with tamsulosin has extremely high clinical application value in the treatment of CP and is recommended to be used clinically.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: